KI-DX-014 is a DDX21 inhibitor with high RNA-binding inhibitory activity (IC50 of 3.31 µM). KI-DX-014 targets DDX21s intrinsically disordered C-terminal domain, inhibits DDX21-structured RNA interaction, modulates DDX21s RNA-dependent ATPase activity, and disrupts DDX21 biomolecular condensate formation. KI-DX-014 attenuates in vitro P-TEFb release from the 7SK snRNP complex, suppresses P-TEFb-dependent RNA polymerase II CTD phosphorylation, and induces developmental defects in zebrafish embryos. KI-DX-014 acts as a chemical probe for dissecting DDX21 functions in normal physiology and disease states. KI-DX-014 can be used for cancers and neurodegenerative disorders research[1].
Molecular Weight:
330.38
Purity:
99.87
CAS Number:
[1309288-83-2]
Formula:
C17H22N4O3
Target:
ATP Synthase,DNA/RNA Synthesis
Application Notes:
MCE Product type: Reference compound
* VAT and and shipping costs not included. Errors and price changes excepted
